Defeat Cancer (51 page)

Usually, we treat our patients using 13.56 MHz radio frequency waves, for an hour to an hour and a half, every other day. We recommend that they do ten treatments.

A healthy body reacts to the threat of illness with regulated temperature increases. In acute cases of illness, these increases may progress, until the person has a high fever, which then triggers an enhanced immune response.

Body temperature plays a crucial role in immune system regulation. Fevers might be considered as a natural, temporary “special program”
which the immune system is set up to follow at times. Accordingly, an artificially induced increase in body temperature can result in the sustained stimulation of otherwise inhibited powers of self-healing, even in cases of disease involving chronic or malignant processes.

Martin Heckel, MD, a German radiologist and doctor of internal medicine, has developed a cancer treatment method which involves irradiating the entire body in a heat-insulated treatment cabin with high intensity infrared rays, which are emitted from four 300-watt halogen wolfram lamps. The intensity of the treatment is adjusted individually for each patient, and for those who are able to tolerate it, a body temperature of more than 40° Celsius (104 degrees Fahrenheit) can be achieved.

Besides counteracting symptoms by stimulating the immune system, a controlled increase in body temperature can also influence faulty regulatory processes within the entire body, promote cell reparation and regeneration, and create sustained muscle relaxation, even in the deepest, most inaccessible muscle layers of the body. It enhances numerous immunological processes, especially lymphocyte migration to sites of inflammation and malignant processes, and increases the efficiency of various antibiotic and chemotherapeutic substances.

In 1996, we had a Norwegian patient with melanoma come into our clinic. He had suffered three recurrences of cancer to his lumbar and thoracic spine, as well as to his ribs and left hip (which had lesions). He had also had surgery, but within a year following his operation, bone metastases were found in his spine, ribs, femur, and pelvis. During the three weeks that he was at our clinic, he received weekly whole body hyperthermia treatments, in which we were able to raise his body temperature to 40-40.5° C (104-105.8 degrees Fahrenheit). He also received mistletoe injections. After he left our clinic, he continued with the mistletoe injections and returned to Humlegaarden on a yearly basis to receive whole body hyperthermia sessions. By 2002, we decided that he no longer
needed treatments, but he continued to do mistletoe treatments on his own. Today, he is doing very well, and has never had a recurrence of cancer since his stay here.

Whole-body hyperthermia is a supportive therapy that can be combined synergistically with other therapies to treat cancer and other diseases.

We will soon be one of the first cancer facilities in Europe to use High Level Whole Body Hyperthermia, which is another efficient cancer treatment method whereby we raise the patient’s body temperature to 43.5 - 44 °C (approximately 110-111.2 degrees Fahrenheit). Raising the body’s temperature to this level kills cancer cells.

For the procedure, the patient is lowered into a 47 degree Celsius (116.6 degrees Fahrenheit) hot water bath, for just under an hour. This is done under the supervision of a team of doctors and nurses. Due to the very high temperature of the water, anesthesia is given to the patient prior to the treatment. After awhile, the patient’s body temperature peaks to 43.4-44 degrees Celsuis (110-111.2 degrees Fahrenheit) for about six minutes, which is sufficient for adequately stimulating the immune system. High Level Whole Body Hyperthermia has been extensively tested, and clinical results show that patients don’t suffer from any side effects from it, and neither have any resulting fatalities ever been reported. We are very encouraged about the results that other clinics have had so far with this new treatment, and are looking forward to implementing it here in Denmark in the near future. We will be the first clinic in Scandanavia to use it.

Since 1970, global angiogenesis research has taken place at the Judah Folkman laboratories at the Dana-Farber Institute in Boston, MA, USA. A majority of the world’s top angiogenesis researchers
have been working here or in close connection with Judah Folkman, the medical doctor who first discovered that all cancer tumors are angiogenesis-dependent. (Angiogenesis is the creation of new blood vessels from existing blood vessels. These blood vessels are the most important way that cancer cells obtain their nutrition.) Dr. Folkman surmised that if a tumor could be stopped from growing its own blood supply, it would wither and die. Unfortunately, he died of a heart attack in January 2008 at Denver International Airport. He was 75 years old. Because of his untimely death, he didn’t win the Nobel Prize in medicine, which he really deserved.

At Humlegaarden, we have acquired extensive knowledge about metronomic chemotherapy, a non-damaging chemotherapy treatment which cuts off the tumor’s blood supply rather than destroying the tumor itself. It does this by destroying endothelial cells within the blood vessels that feed the cancer. While full-dose chemotherapy also destroys the endothelial cells which are in the small blood vessels, in the usual two to three week break that is given in-between chemotherapy sessions, these cells have time to grow and reestablish themselves, so that the blood vessels are able to reach into the cancer again.

Metronomic chemotherapy, which is given daily or every other day, doesn’t allow blood vessels to get reestablished. It doesn’t matter what type of cancer cells are involved or if those cells have become resistant to full-dose chemotherapy and/or other treatments, because doctors don’t attack cancer cells with metronomic therapy; they attack the blood vessels that feed the cancer.

On February 23, 2008 at the 28th annual German Cancer Congress, the American cancer researcher D. McDonald, MD, from San Francisco, presented an interesting lecture at a symposium entitled: “Anti-angiogenesis Therapy for Solid Tumors.” At this lecture, he showed pictures from his research, which illustrated that as soon as a day after treatment with an anti-angiogenesis remedy is stopped, the endothelial cells (the cancer’s blood vessel wall cells) start sprouting and sending out growth processes from the basal membrane.
Within just a week of stopping anti-angiogenesis treatment, the blood vessels and the blood supply to the cancer tumor are able to fully reestablish themselves, which is why metronomic chemotherapy is given daily or every other day.

Over the long run, endothelial cells can become resistant to treatments just like cancer cells, but they take much longer than cancer cells to develop this resistance. When a patient who is doing metronomic chemotherapy has a shrunken tumor that ceases to remain stable and starts to grow again, this indicates that endothelial resistance has occurred. The period of stability which patients experience with metronomic therapy can last for years, but at some point, as blood vessels become resistant to angiogenesis treatments, the cancer can start to grow again. At that point, patients should change to a different treatment agent or combination of metronomic substances.

Because of its extreme usefulness in stopping angiogenesis, we give metronomic chemotherapy to our patients whenever needed. It represents one of the greatest medical advances in the entire history of cancer treatment.

For patients, this newer way of treating cancer is beneficial because it has practically no side effects. Many different substances can be used in metronomic chemotherapy, most of which are prescribed in tablet form. Research has shown their effects upon cancer to be comparable to what patients would experience from regular, full-dose chemotherapy. The only difference is that with full-dose chemotherapy, high-dose drugs are given every second or third week, and they tend to produce serious side effects.

One hundred tablets of cyclophosphamide, a natural substance that’s sometimes used in metronomic chemotherapy, costs approximately 30 US dollars: enough for 3.5 months of treatment, so cancer patients who don’t have a lot of money can use this as part of a formidable treatment plan.

One of the main therapies that we utilize at Humlegaarden is mistletoe injections. The mistletoe that we use comes from different trees: most commonly, spruce, apple and pine trees. The first person to suggest mistletoe for cancer treatment was Rudolph Steiner, an Austrian-Swiss philosopher who founded the Anthroposophical Society in 1912. Mistletoe injections have been used in Europe to treat cancer for almost 100 years, since 1917. Since that time, millions of patients have been treated with it. A recent survey revealed that 60 percent of cancer patients in Germany use mistletoe as part of their treatment protocols. It’s also popular in Switzerland, France, and Austria.

Mistletoe affects cancer in several ways. First, it kills cancer cells directly, without harming healthy cells. It does this through the actions of lectins and viscotoxins, which are proteins produced by the plant’s leaves and stems. These proteins are toxic to cancer cells and cause necrosis (premature cell death), and apoptosis (programmed cell death, in which the cancer cell self-destructs). They also stimulate the immune system. Lectins are considered to be the most important substances in mistletoe. In addition to killing cancer cells, mistletoe increases endorphins, and has many other positive effects upon the body. More than 200 studies have been done on this incredible plant.

People with cancer who receive mistletoe injections have a better quality of life and higher tolerance for chemotherapy, as well as increased longevity, or survival from cancer.

We start our patients on a small dose of mistletoe and slowly increase it, as we look for local skin reactions which are often present at the beginning of treatment. Fortunately, these reactions typically resolve after a few injections, and if not, we are usually able to find a different dose or preparation which patients can tolerate. Iscador or Helixor are the two most common mistletoe products in Europe, and we have very good results with these. Sometimes, the results are absolutely astounding.

Mistletoe therapy is mostly prescribed by medical doctors, and we have thousands of well-documented case stories of cancer patients who have done mistletoe injections for up to fifteen or twenty years.

I once had a patient from Norway who had a tumor that measured 25 cm (approximately 9.8 inches) by 12-14 cm (4.7-5.5 inches) on the left side of his liver, along with metastases on the right side. He was told that he had a month or two to live. If you had seen him, you wouldn’t have believed your eyes. He was 77 years old and his liver was huge! He came to my clinic for three weeks. I gave him Helixor (a mistletoe compound), at a dosage of 100 mg, three times per week, along with hyperthermia treatments. Three years later, I spoke with him and discovered that his quality of life was good; he was fishing every day, and going out to enjoy the hills of Norway every Sunday. He lived for seven years following his treatment at my clinic, until he was 84 years old. His case is an example of how mistletoe, even when used alone, can produce excellent results and significantly improve and extend one’s life.

Mistletoe can be used as a standalone treatment, but it can also be combined with chemotherapy and other therapies. There are rules for its use, though. For instance, it shouldn’t be given if patients have a fever above 37.7 Celsius (99.86 degrees Fahrenheit), or on the same day that they receive intravenous treatments of any kind, including chemotherapy. It can, however, be given on the day before or the day after such treatments. In fact, mistletoe enables patients to tolerate chemotherapy and radiation treatments better. A Danish architect that I know did mistletoe injections while undergoing chemotherapy. He was the only one in the cancer ward at his local hospital who was taking mistletoe. Doctors couldn’t understand why his white blood cell counts stayed so high during chemotherapy. Many studies have shown that people tolerate conventional treatments better when they take mistletoe, because it keeps their immune parameters high.

Low-dose naltrexone (LDN) is another excellent cancer treatment remedy that we have been giving our patients for over ten years. Many Internet websites describe the benefits of low-dose naltrexone for treating cancer, so its use in treating cancer is becoming well-known. It’s also beneficial for treating autoimmune diseases. Patients that take this drug feel dramatically better within days because it releases endorphins, kills cancer cells via apoptosis, and reduces inflammation.

The first person to take this medication for cancer was a woman from France, who had four brain metastases from melanoma. This is a very aggressive cancer, and there was nothing that conventional oncologists could do for her. She had heard about Dr. Bernard Bihari, the medical doctor who discovered the clinical effects of LDN, and went to hear him speak in Paris. She asked him for some LDN, which he gave her. She began to take it, in a dose of three milligrams daily. Seven months later, her brain metastases disappeared! She took LDN for twelve years, but after twelve years, she stopped, as every time she took a pill, she was reminded of the fact that she had cancer. About seven months later, she began to have multiple metastases on her lungs and on the skin of her arms. She called Dr. Bihari, and resumed taking LDN for another seven months, during which time her lung and skin metastases disappeared. She was forty-two years old at the time, and I don’t know what has happened to her since then. Now, LDN is given to many cancer patients. It’s completely non-toxic and is very effective for treating some cancers, especially when given in conjunction with alpha-lipoic acid.

There are many effective treatment options for prostate cancer, but there is a trade-off between treatment efficacy and the patient’s ability to be sexually active. Understanding patients’ attitudes and preferences is important when choosing what treatments to give
them, especially when they are first diagnosed. Fortunately, all three of the following types of patients can be efficiently treated: